Metachronous Osteosarcoma, A Differential Diagnosis to be Considered in Children With Osteosarcoma: A Review of Literature and a Case From Our Center.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
25
01
2022
accepted:
21
07
2022
pubmed:
18
10
2022
medline:
28
3
2023
entrez:
17
10
2022
Statut:
ppublish
Résumé
Metachronous osteosarcomas (MOS) are currently defined as tumors that arise in a way and site unusual for typical metastasis. In this article, we reviewed the recent literature on the occurrence of metachronous osteosarcoma and presented a case from our center. Our patient, a 10-year-old girl, presented with metachronous osteoblastic osteosarcoma of the left distal femur ∼5 years after the successful treatment for osteosarcoma of the right distal femur. Even after several relapses, complete remission (CR) was achieved after the first osteosarcoma and after the metachronous osteosarcoma. The literature research revealed that metachronous osteosarcoma occurs in 3.4 to 5.4% of osteosarcoma patients. The time interval between the diagnosis of the initial osteosarcoma and the metachronous tumor ranged from 0.2 to 14.3 years (median 2.5 y). MOS appears to have differences in localization and metastatic spread, as well as a different survival pattern compared with primary osteosarcoma and osteosarcoma recurrence. Survival (median 4.3 y, range 0 to 24.6 y) appears to be associated with the time interval to diagnosis of MOS. In particular, early MOS (<24 mo after primary diagnosis) seem to have a poorer prognosis. Therefore, the occurrence of MOS at oncological unusual sites should be considered as a differential diagnosis in osteosarcoma survivors.
Identifiants
pubmed: 36251795
doi: 10.1097/MPH.0000000000002560
pii: 00043426-202304000-00001
pmc: PMC10030169
doi:
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-110Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol. 2017;38:33–43.
Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–234.
Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur J Cancer. 2013;49:684–695.
Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
Vijayamurugan N, Bakhshi S. Review of management issues in relapsed osteosarcoma. Expert Rev Anticancer Ther. 2014;14:151–161.
Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer. 1975;32:87–107.
Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:559–568.
Jaffe N, Pearson P, Yasko AW, et al. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer. 2003;98:2457–2466.
Pirker-Frühauf UM, Friesenbichler J, Rabitsch K, et al. Three metachronous osteosarcomas within 22 years without pulmonary metastases: A case report and review of the literature. Case Rep Orthop. 2013;2013:1–4.
Brandal P, Bjerkehagen B, Bruland ØS, et al. Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience. Acta Oncol (Madr). 2009;48:1165–1172.
Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30:445–451.
Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009;152:289–308.
Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe. 1983;4:135–141.
Rodriguez EK, Hornicek FJ, Gebhardt MC, et al. Metachronous osteosarcoma: A report of five cases. Clin Orthop Relat Res. 2003;411:227–235.
Stevens M, Frobisher C, Hawkins M, et al. Solitary skeletal osteosarcoma recurrence. findings from the cooperative osteosarcoma study group. Pediatr Blood Cancer. 2008;50:1018–1025.
Aung LL, Gorlick R, Healey JH, et al. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol. 2003;21:342–348.
Fitzgerald RHJ, Dahlin DC, Sim FH. Multiple metachronous osteogenic sarcoma. Report of twelve cases with two long-term survivors. J Bone Joint Surg Am. 1973;55:595–605.
Marcove RC, Heelan R, Lindeque B, et al. Treatment of a second bone osteosarcoma: 3 cases and an unusual MRI finding. Acta Orthop. 1994;65:480–482.
Kinderkrebsregister D Deutscher Kinderkrebsregister Auswertung Osteosarkom. Available at: https://www.kinderkrebsregister.de/dkkr/ergebnisse/auswertungen-im-detail/knochentumoren/osteosarkome/dost-u18.html . Accessed January 01, 2015.
Ferrari S, Mercuri M, Bacci G, et al. Comment on “prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols” [5] (multiple letters). J Clin Oncol. 2002;20:2910–2911.
Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–532.
Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:710–715.
Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: The Rizzoli experience in 52 patients. Acta Orthop. 2006;77:938–943.
Carrle D, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res. 2009;152:165–184.
L. Lung-Seeking Metastases. 2019:1-18.
Tian H, Guan D, Li J. Identifying osteosarcoma metastasis associated genes by weighted gene co-expression network analysis (WGCNA). Med (United States). 2018;97:1–8.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437.
Irmisch A, Huelsken J. Metastasis : New insights into organ-specific extravasation and metastatic niches. Exp Cell Res. 2013;319:1604–1610.
Amstutz HC. Multiple osteogenic sarcomata — Metastatic or multicentric? Report of two cases and review of literature. Cancer. 1969;24:923–931.
Mahoney JP, Spanier SS, Morris JL. Multifocal osteosarcoma. A case report with review of the literature. Cancer. 1979;44:1897–1907.
Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–2018.
Lin Y-H, Jewell BE, Gingold J, et al. Osteosarcoma: Molecular pathogenesis and iPSC Modeling. Trends Mol Med. 2017;23:737–755.
Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661–671.
Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in Cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6:724–734.
Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893–899.
Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:557–565.